Oncopeptides AB (publ)
ONPPF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$56.69M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $56.69 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-1.87 |
| Beta | -0.55 |
| Outstanding Shares | 213,912,821 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -3.8 |
|---|---|
| PEG | 36.57 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Oncopeptides AB (publ)
69 employees
CEO: Sofia Heigis
Oncopeptides AB (publ) is a biotechnology firm dedicated to developing medical therapies for cancer, serving markets across the United States, Europe, and worldwide. Its foremost experimental compound, melflufen, is a distinct peptide-dr...